Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis by Liang Zong & Ping Chen
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Zong and Chen World Journal of Surgical Oncology 2014, 12:71
http://www.wjso.com/content/12/1/71RESEARCH Open AccessPrognostic value of KIT/PDGFRA mutations in
gastrointestinal stromal tumors: a meta-analysis
Liang Zong1,2* and Ping Chen1Abstract
Background: The postulated relationship between KIT/PDGFRA mutations and their prognostic value in
gastrointestinal stromal tumors (GISTs) has generated intense attention during the past decade, despite the fact
that a great deal of studies have been conducted on this subject. To provide a strong quantitative estimate of this
postulated relationship, we carried out a meta-analysis which combined, compared, and summarized the results of
existing relevant studies.
Methods: Studies were identified by searching databases and reviewing citations in relevant articles. Of 48
potentially relevant studies, we combined individual patient data from 18 studies which involved 1,487 patients
with GISTs, by which we made a comparison between the positive KIT mutation subgroup and the negative KIT
mutation subgroup (PDGFRA mutation and wild type). We tabulated and analyzed the patient characteristics from
each study, including general information such as age and gender, histopathological parameters, and clinical
follow-up outcomes.
Results: KIT mutations, compared with PDGFRA mutations and wild type, showed a marked increased risk not only
for tumor size (>5 cm) but also for higher mitotic activity (>5), suggesting that KIT mutations significantly correlated
with the National Comprehensive Cancer Network (NCCN) high risk or National Institutes of Health (NIH) high risk
(1.74 (95% CI, 1.20 to 2.53) and 2.00 (95% CI, 1.08 to 3.68), respectively). Moreover, higher recurrence and metastasis
was observed in GISTs with KIT mutations, revealing its closer correlation with clinical malignant risk (P <0.001 for
each, with odds ratio (OR) of 2.06 (95%, 1.37 to 3.11) and 2.77 (95%, 1.64 to 4.67), respectively). High risk or
malignant GISTs with KIT mutations had a significantly poorer prognosis, as measured by 3-year overall survival,
compared to those with PDGFRA mutations and wild type (0.47 (95% CI, 0.25 to 0.90)).
Conclusions: KIT mutations, compared with PDGFRA mutations and wild type, represent a poorer prognostic
marker in high risk or malignant GISTs.
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Gastrointestinal stromal tumors (GISTs) are rare tumors,
but are the most common primary mesenchymal tumor
of the gastrointestinal tract [1]. GISTs express the tyro-
sine kinase receptor, KIT, which is the protein product
of the KIT protooncogene. GISTs are generally charac-
terized by gain-of-function mutations of KIT [2], and
less often by PDGFRA or BRAF gene mutations [3-5]. In
fact, the frequency of KIT/PDGFRA mutations in GISTs* Correspondence: 250537471@qq.com
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article, unless otherwise stated.varies due to sample size, race, and geographic area.
Around 85% of GISTs harbor mutations in KIT or
PDGFRA [6].
To our knowledge, GISTs have a wide spectrum of
biological behaviors ranging from benign to malignant.
Due to the tumor’s specific biological behavior, there is
no standard definition of benignity and malignancy
when a patient is diagnosed with GIST at an early stage.
In 2001, the National Institutes of Health (NIH) recom-
mended the use of risk assessment in predicting GIST
behavior, in preference to trying to distinguish between
benign and malignant lesions. They categorized GISTs
into four groups on the basis of the combined parameterstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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low risk, intermediate risk, and high risk [7]. In 2006, an-
other risk system for malignancy adding tumor site was
established by the National Comprehensive Cancer Net-
work (NCCN) criteria, based on Miettinen and Lasota’s
[8] Armed Forces Institute of Pathology (AFIP) stratifica-
tion [9]. Although these systems are useful in predicting
GIST behavior, it is based on the assumptions of a wide
range of experts on GISTs.
KIT mutations were reported to associate with tumor
metastasis and poor clinical outcome in GISTs [10]. On
the contrary, PDGFRA mutations were typically charac-
terized by clinically benign tumors [11,12]. Furthermore,
the mutational status of KIT and PDGFRA is also a sig-
nificant predictive factor for response to imatinib [13].
KIT and PDGFRA mutations appear to be related to out-
come, but have not yet been integrated into the risk clas-
sification schemes. Previous studies were unable to
distinguish the potential value of primary gene alter-
ations in the risk of malignant biological behavior among
gene subgroups or in controls to potentially confirm the
variables examined [3,14-30]. This was possibly due to
small sample sizes or confounding variables.
Therefore, we initiated an international collaborative
effort which resulted in a meta-analysis of data on indi-
vidual patients in prospective cohort studies to evaluate
the prognostic value of KIT/PDGFRA mutations in
GIST. To supply more powerful evidence, not only the
tumor size, mitotic count, and tumor site, which have
been used as parameters in NCCN criteria, but also clin-
ical follow-up results such as recurrence, metastasis, and
overall survival were tabulated and analyzed in our study.Methods
Publication search
Two electronic databases (PubMed and Embase) were
searched (last search was updated on 1 May 2012), using
the search terms: ‘gastrointestinal stromal tumor’ and
‘KIT/PDGFRA mutation’. All eligible studies were re-
trieved, and their bibliographies were checked for other
relevant publications. Review articles and bibliographies
of other relevant studies identified were hand-searched
to identify additional eligible studies. Only published
studies with full-text articles were included. When the
same patient population was included in several publica-
tions, only the most recent or complete study was used
in this meta-analysis (Figure 1).Inclusion criteria
The inclusion criteria were as follows: 1) KIT/PDGFRA
mutations and prognosis; 2) KIT/PDGFRA mutations
in primary tumor before the treatment of imatinib;
and 3) sufficient published data (more than 20 cases)to estimate an odds ratio (OR) with 95% confidence
interval (CI).
Data extraction
Information was carefully extracted from all eligible
studies by two of the authors (LZ and PC), according to
the inclusion criteria. The following data were collected
from each study: study design (cohort, case-control, or
cross-sectional), study population, sample size, total
number of patients with positive KIT mutations and
negative KIT mutations, and number of patients divided
by age, gender, KIT expression, cell type, primary site,
tumor size, mitotic count, recurrence, metastasis, and
3-year overall survival in those with and without KIT
mutations, respectively.
Statistical analysis
The ORs with 95% CI were used to assess the predictive
value of KIT mutations on the malignant risk of GISTs,
according to the method of Woolf. Heterogeneity as-
sumption was confirmed by the χ2-based Q-test. A P
value greater than 0.10 for the Q-test indicated a lack of
heterogeneity among the studies, therefore the OR esti-
mate for each study was calculated by the fixed effects
model (the Mantel-Haenszel method). Otherwise, the
random effects model (the DerSimonian and Laird
method) was used. The significance of the pooled OR
was determined by the Z-test and P >0.05 was consid-
ered statistically significant. Sensitivity analyses were car-
ried out to determine if modification of the inclusion
criteria for this meta-analysis affected the final results.
An estimate of potential publication bias was carried out
using the funnel plot, in which the OR for each study
was plotted against its log (OR). An asymmetric plot
suggested possible publication bias. Funnel plot asym-
metry was assessed using Egger’s linear regression test, a
linear regression approach to measure funnel plot asym-
metry on the natural logarithm scale of the OR. The sig-
nificance of the intercept was determined by the t-test,
as suggested by Egger (P <0.05 was considered represen-
tative of statistically significant publication bias). All
statistical tests were performed with Review Manager,
version 4.2 (The Cochrane Collaboration, Oxford, UK)




A total of 43 publications met the inclusion criteria
[3,10,14-54]. A series of studies with single factor analysis
of KIT gene mutations were excluded due to lack of con-
trolled gene subgroups [10,31-36]. Studies by Wardelmann
et al. and Koyama et al. were also excluded because
they screened metastatic GIST patients specializing in
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Figure 1 Flow chart of literature selection.
Table 1 Main characteristics of all studies included in the me
Study District Study period Study size Age
(mean, years) (ma
Daniels [3] Germany 2011 87 64.9
Taniguchi [14] Japan 1999 124 60
Sakurai [15] Japan 1999 48 59.4
Yamamoto [16] Japan 2004 27 59
Lin [17] Taiwan 2006 25 63.2
Kim [18] Korea 2004 86 59.5
Liu [19] China 2005 82 53
Tzen [20] Taiwan 2007 134 NA
Cho [21] Japan 2006 56 61
Keun [22] Korea 2008 68 56
Andersson [23] Sweden 2006 177 NA
Haller [24] Germany 2005 38 64
Steigen [25] Norway 2007 89 64.8
Zheng [26] China 2011 25 58
Wardelmann [27] Germany 2003 55 62
Martín [28] Spain 2005 162 63
Penzel [29] Germany 2005 79 60.9
Agaram [30] America 2006 125 NA
BM, benign to malignant; NA, not available; NCCN, National Comprehensive Cancer
Ki-67 index; M-MIB index, mitotic rate and MIB-1 index; MTR-KI67 index, maximum
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tinib [37,38]. In addition, the study by Kikuchi et al. was
excluded because it focused on heterozygosity as a useful
post-recurrence prognosis in screened patients with liver
metastasis [39]. The studies by Zheng et al. were also ex-
cluded because the included articles contained the same
patient population [40,41]. Other studies were excluded
due to insufficient information to calculate OR [42-54].
Hence, a total of 18 studies including 1,487 patients were
used in the pooled analyses. Table 1 lists the studies identi-
fied and their main characteristics. Of the 18 groups, the
sample size ranged from 25 to 177.
General and pathological outcomes
The meta-analysis of both age distribution and gender in
the KIT mutation-positive versus -negative subgroups
did not attain statistical significance (1.08 (95% CI, 0.72
to 1.61; P = 0.72) and 1.02 (95% CI, 0.77 to 1.35; P = 0.90),
respectively) (Figure 2a,b). The overall OR for KIT ex-
pression in the KIT mutation-positive versus -negative
subgroups was 2.79 (95% CI, 1.49 to 5.21; P = 0.001)
(Figure 2c). The overall OR for spindle cells in the KIT
mutation-positive versus -negative subgroups revealed
a significantly elevated risk in the KIT mutation-positive
subgroup, but for the stomach as a primary site, this
was seen in the KIT mutation-negative subgroup (3.19
(95% CI, 1.71 to 5.93; P = 0.0003) and 0.56 (95% CI,ta-analysis
Gender
le/female)
Subgroups Prognostic system Follow-up time
(mean, years)
45/42 KIT/PDGFRA/BRAF/WT NCCN risk NA
NA KIT positive/negative BM 4.1
21/27 KIT positive/negative BM 3.7
15/24 KIT/PDGFRA/WT M-MIB index 3.6
13/12 KIT positive/negative NA NA
47/39 KIT positive/negative NIH risk NA
56/26 KIT positive/negative BM 4.1
74/60 KIT/PDGFRA/WT NA 3.9
35/21 KIT/PDGFRA/WT BM 4.7
31/37 KIT/PDGFRA/WT NIH risk 5.0
NA KIT/PDGFRA/WT MTR-KI67 index 6.2
22/16 KIT/PDGFRA/WT NIH risk 2.7
50/39 KIT/PDGFRA/WT BM NA
15/10 KIT/PDGFRA/WT MC-KI67 index 3.2
29/26 KIT/PDGFRA/WT BM NA
82/80 KIT positive/negative NIH risk 3.5
41/38 KIT/PDGFRA/WT NIH risk NA
NA KIT/PDGFRA/WT NA NA
Network; NIH, National Institutes of Health; MC-KI67 index, mitotic count and
tumor size and Ki67 index; WT, wild type.
Figure 2 General and pathological outcomes of KIT mutation-positive subgroup versus KIT mutation-negative subgroup. (a) Age; (b)
gender; (c) KIT expression; (d) cell type; (e) primary tumor site; (f) tumor size; and (g) mitotic count.
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However, an increased risk for larger tumor size (>5 cm)
and higher mitotic activity (>5) was observed in the KIT
mutation-positive subgroup (1.74 (95% CI, 1.20 to 2.53;
P = 0.003) and 2.00 (95% CI, 1.08 to 3.68; P = 0.03), respect-
ively) (Figure 2f,g).
Clinical outcomes
The KIT mutation-positive subgroup showed a signifi-
cantly higher rate of recurrence and metastasis com-
pared to the KIT mutation-negative subgroup (2.06 (95%
CI, 1.37 to 3.11; P = 0.0005) and 2.77 (95% CI, 1.64 to
4.67; P = 0.0001), respectively) (Figure 3a,b). Moreover,
KIT mutations demonstrated a worse prognosis in high
risk or malignant GISTs, which was supported by the
3-year overall survival analysis (OR 0.47 (95% CI, 0.25 to
0.90; P = 0.02)) (Figure 3c).
Publication bias
Begg’s funnel plot was performed to assess publication
bias. The heterogeneity tests for comparing the 18 com-
bined studies showed heterogeneity in some analyses
such as cell type and mitotic count; however, significant
heterogeneity among the studies was not found (Table 2).No single study influenced the pooled OR qualitatively
as indicated by the sensitivity analyses (data not shown).
Discussion and conclusion
NIH and NCCN systems were established to predict
GIST behavior using risk assessment (very low risk, low
risk, intermediate risk, and high risk). However, it is still
not clear whether internal molecular events correlate
with malignant risk in GISTs. Molecular findings are
critical in understanding the pathogenesis of GISTs. In
1998, Hirota et al. made the landmark discovery that the
majority of GISTs harbor an activating mutation in the
KIT oncogene [2]. Just 5 years later, Heinrich et al. iden-
tified oncogenic mutations in PDGFRA in a small subset
of GISTs lacking KIT mutations, which meant that the
mutations in PDGFRA and KIT were mutually exclusive
[4]. Since then, subsequent evidence has shown that
these mutations are pathogenetic for GIST initiation.
However, between 10% and 15% of GISTs do not have
KIT or PDGFRA mutations (known as wild type GISTs)
and are a heterogeneous group, and in a recent study
mutations in BRAF were found [3].
To date, many studies have focused on stratifying
GISTs into prognostic categories based on mutational
Figure 3 Clinical outcomes of KIT mutation-positive subgroup versus KIT mutation-negative subgroup. (a) Recurrence; (b) metastasis; and
(c) 3-year overall survival.
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But these studies showed controversial results and raised
high concern. For example, Taniguchi et al. showed that
KIT mutation was an independent prognostic factor for
overall and cause-specific survival in patients with
GISTs, whereas Sakurai et al. and Yamamoto et al. failed
to observe such an association [14-16]. Lin et al. sug-
gested that KIT mutation, compared with PDGFRA mu-
tation and wild type, was often found in male patients
and was more frequently found in those with large
GISTs; however, they did not determine the predictive
value of KIT and PDGFRA mutations [17]. In contrast,
Kim et al. suggested that KIT mutation, along with high
mitotic count and larger tumor size, had a strong prog-
nostic value [18]. Prospective data have been criticized
as being less convincing due to small sample size and the
lack of statistical power to integrate sporadic individualstudies. With a goal to explore the prognostic value of KIT/
PDGFRA mutations, we performed this meta-analysis to
derive an overall pooled estimation of published studies.
Since KIT mutations were proportionally more frequent
than PDGFRA mutations and wild type, we divided all
GISTs into KIT mutation-positive and -negative subtypes
(PDGFRA mutations and wild type).
In analysis of mutation subtypes and biological behavior
of GISTs, the results were as follows: 1) KIT mutations
correlated with higher KIT expression level than PDGFRA
mutations and wild type; 2) KIT mutations had a prefer-
ence for spindle cell in histology; 3) PDGFRA mutations
and wild type more frequently occurred in the stomach;
and 4) KIT mutations showed a marked increased risk in
both larger tumor size (>5 cm) and higher mitotic count
(>5), which revealed that KIT mutations significantly cor-
related with NCCN high risk or NIH high risk.
Table 2 Outcomes of the meta-analysis
Parameter Includedstudies
Sample size
Heterogeneity OR 95% CI ofoverall effect P valueKIT mutation-positive KIT mutation-negative
Age (≥40 years) 7 308 179 P = 0.26, I2 = 22.4% 1.08 0.72 to 1.61 P = 0.72
Gender (male) 12 517 348 P = 0.35, I2 = 9.7% 1.02 0.77 to 1.35 P = 0.90
KIT expression 5 224 200 P = 0.29, I2 = 20.2% 2.79 1.49 to 5.21 P = 0.001
Cell type (spindle cell) 9 450 278 P = 0.007, I2 = 61.7% 3.19 1.71 to 5.93 P = 0.0003
Primary tumor site (stomach) 11 629 356 P = 0.41, I2 = 3.2% 0.56 0.43 to 0.74 P <0.0001
Tumor size (>5 cm) 8 319 218 P = 0.05, I2 = 50.8% 1.74 1.20 to 2.53 P = 0.003
Mitotic count (>5) 8 382 263 P = 0.02, I2 = 57.8% 2.00 1.08 to 3.68 P = 0.03
Recurrence 8 424 268 P = 0.10, I2 = 42.1% 2.06 1.37 to 3.11 P = 0.0005
Metastasis 6 239 153 P = 0.31, I2 = 16.5% 2.77 1.64 to 4.67 P = 0.0001
3-year overall survival 6 95 106 P = 0.24, I2 = 25.8% 0.47 0.25 to 0.90 P = 0.02
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the relationship between mutation subtypes and clinical
follow-up outcomes, which revealed that KIT mutations
correlated with higher malignant risks than PDGFRA muta-
tions and wild type, mainly because of: 1) more frequent re-
currences; 2) higher metastasis; and 3) a worse survival rate.
It is very interesting that KIT mutations in high risk or
malignant GISTs represent a worse factor of prognosis than
PDGFRA mutations and wild type based on our findings,
but patients with KIT mutations benefit a lot from the tar-
geted therapy of imatinib. On reviewing the latest studies,
our previous results supported that patients with KIT mu-
tations have improved response to imatinib treatment when
compared with those with wild type. However, the long-
term efficacy is not significant [13]. Moreover, patients with
KIT mutations who initially benefit from imatinib treat-
ment eventually develop drug resistance. Recent studies
reported that those patients with secondary imatinib re-
sistance are through polyclonal acquisition of second-site
mutations in the kinase domain. Regardless of this, it has
been proved that constitutive KIT/PDGFR activation pro-
motes proliferation and inhibits apoptosis of neoplastic
cells through the CCRP signaling pathway [55]. An alter-
ation in CCRP is often implicated in the pathogenesis and
tumor progression of various types of tumors. Therefore,
secondary mutation and CCRB signaling pathway might
be the possible mechanism to explain the discrepancy of
KIT mutations in prognosis and target therapy.Abbreviations
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